Kistner O, Barrett P N, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F
Biomedical Research Center, Immuno AG, Orth/Donau, Austria.
Dev Biol Stand. 1999;98:101-10; discussion 111.
Influenza vaccine production is dependent on the availability of embryonated hen eggs for virus growth. This is an extremely cumbersome system with many disadvantages with respect to selection of virus variants and the presence of adventitious viruses. We have developed an alternative cell culture system which allows rapid production of large volumes of vaccine. The WHO-approved Vero cell line was used in serum-free culture to grow many influenza strains to high titre. This system could be scaled-up to allow vaccine production with a 1200 litre fermenter. A purification scheme was developed which resulted in a high purity whole virus vaccine. This was demonstrated to be at least as immunogenic as a conventional egg-derived preparation.
流感疫苗的生产依赖于用于病毒生长的受精鸡蛋。这是一个极其繁琐的系统，在病毒变种的选择以及潜在病毒的存在方面存在诸多缺点。我们开发了一种替代细胞培养系统，该系统能够快速生产大量疫苗。世界卫生组织批准的Vero细胞系用于无血清培养，以使多种流感毒株生长至高滴度。该系统可以扩大规模，使用1200升发酵罐进行疫苗生产。我们制定了一种纯化方案，从而得到高纯度的全病毒疫苗。事实证明，这种疫苗的免疫原性至少与传统的鸡蛋衍生制剂相当。
